Individual variation in vaccine immune response can produce bimodal distributions of protection.
Correlates of protection
Immunogenicity
Leaky vaccines
Models of vaccine efficacy
Vaccine efficacy
Waning immunity
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
26 10 2023
26 10 2023
Historique:
received:
14
02
2023
revised:
14
09
2023
accepted:
14
09
2023
medline:
23
10
2023
pubmed:
5
10
2023
entrez:
4
10
2023
Statut:
ppublish
Résumé
The ability for vaccines to protect against infectious diseases varies among individuals, but computational models employed to inform policy typically do not account for this variation. Here we examine this issue: we implement a model of vaccine efficacy developed in the context of SARS-CoV-2 in order to evaluate the general implications of modelling correlates of protection on the individual level. Due to high levels of variation in immune response, the distributions of individual-level protection emerging from this model tend to be highly dispersed, and are often bimodal. We describe the specification of the model, provide an intuitive parameterisation, and comment on its general robustness. We show that the model can be viewed as an intermediate between the typical approaches that consider the mode of vaccine action to be either "all-or-nothing" or "leaky". Our view based on this analysis is that individual variation in correlates of protection is an important consideration that may be crucial to designing and implementing models for estimating population-level impacts of vaccination programs.
Identifiants
pubmed: 37793975
pii: S0264-410X(23)01095-2
doi: 10.1016/j.vaccine.2023.09.025
pii:
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6630-6636Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Cameron Zachreson reports financial support was provided by Australian Government Department of Health and Aged Care. Nicholas Geard reports financial support was provided by Australian Government Department of Health and Aged Care. Allen Cheng reports financial support was provided by Australian Government Department of Health and Aged Care. Joshua Szanyi reports a relationship with Moderna Inc that includes: funding grants. Co-author Allen Cheng is a member of Australian government advisory committees; the views in this paper may not necessarily reflect those of the Australian government.